eCite Digital Repository

A multi-center, observational study shows high proportion of Australian rheumatoid arthritis patients have inadequate disease control

Citation

Littlejohn, G and Roberts, L and Arnold, M and Bird, P and Burnet, S and de Jager, J and Griffiths, H and Nicholls, D and Scott, J and Zochling, J and Tymms, KE, A multi-center, observational study shows high proportion of Australian rheumatoid arthritis patients have inadequate disease control, International Journal of Rheumatic Diseases, 16, (5) pp. 532-538. ISSN 1756-1841 (2013) [Refereed Article]

Copyright Statement

Copyright 2013 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia

DOI: doi:10.1111/1756-185X.12163

Abstract

OBJECTIVES: To evaluate the disease activity and current pharmacological interventions used to achieve remission in rheumatoid arthritis (RA) patients in Australia. METHODS: Rheumatoid arthritis patients treated in participating Australian clinics were included in the study. Patient demographics, disease onset, medications and disease measures were analyzed. Data, de-identified to the patient, clinic and clinician were captured using an electronic clinical management program. The disease activity score (DAS28) was used to classify patients into the disease activity states of remission, low disease activity (LDA), moderate disease activity (MDA) and high disease activity (HDA). Choice of therapy was at the discretion of the treating clinician. RESULTS: A total of 5686 patients, 72.9% female, 26.9% male, with mean age 61.1 (SD 13.6) years and mean disease duration of 11.5 (SD 10.5) years were analyzed. DAS28 ESR (erythrocyte sedimentation rate) scores were recorded for 2973 patients, with 41.6% in remission, 18.6% LDA, 31.6% MDA and 8.2% HDA. Of those in remission, 17% received a biological disease modifying anti-rheumatic drug (bDMARD), 73% methotrexate (MTX), 19% leflunomide (LEF) and 28% prednisolone. Of the patients with MDA, 20% received a bDMARD, 76% MTX, 24% LEF and 39% prednisolone. Of the patients in HDA, 27% received a bDMARD, 78% MTX, 31% LEF and 60% with prednisolone. CONCLUSIONS: Cross-sectional assessment of this large cohort of Australian RA patients found a large proportion remain in moderate or high disease activity; suggesting a considerable evidence-practice gap. Improvement in disease control in this group may reduce future health burdens.

Item Details

Item Type:Refereed Article
Keywords:biologic, disease activity, disease-modifying anti-rheumatic drugs, remission, rheumatoid arthritis
Research Division:Medical and Health Sciences
Research Group:Clinical Sciences
Research Field:Rheumatology and Arthritis
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Skeletal System and Disorders (incl. Arthritis)
Author:Zochling, J (Dr Jane Zochling)
ID Code:87331
Year Published:2013
Web of Science® Times Cited:12
Deposited By:Menzies Institute for Medical Research
Deposited On:2013-11-13
Last Modified:2017-11-02
Downloads:0

Repository Staff Only: item control page